- talk title/abstract will follow
Immune Biomarkers in Cancer: Rational and Perspectives (#50)
1 Université Paris Descartes, Paris, France
Immunotherapies targeting PD-1 and PD-L1 have revolutionized cancer management with approximately 30% of responders. Tools for selecting eligible patients and improving the response rate are needed.
Tumor microenvironment (TME) varies from one patient to another, even in the same tumor type. Some of its immune components car predict prognosis better than conventional classification. For immunotherapy prediction of response, companion test exist merely in few indications.
Multiple complex biomarkers emerge in parallel with innovative and powerful technologies. Yet, the universal biomarker doesn't exist.
I will discuss the multiparametric exploration of the TME with new immunofluorescence approaches. Particularly, the exploration of lymphocyte inhibitory receptor and functionality. And the perspective to link these biomarkers with prognosis and prediction in cancer treatment by immunotherapy.
Keywords: Biomarkers, Cancer, Tumor microenvironment